AcuCort AB (publ) (NGM: ACUC)

Market Cap	97.96M
Revenue (ttm)	7.01M
Net Income (ttm)	-14.21M
Shares Out	119.17M
EPS (ttm)	-0.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,138,284
Average Volume	1,009,358
Open	0.890
Previous Close	0.890
Day's Range	0.828 - 0.950
52-Week Range	0.346 - 1.260
Beta	1.12
RSI	64.81
Earnings Date	Feb 14, 2025

About AcuCort AB

AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 3
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: ACUC

Financial Performance

In 2023, AcuCort AB's revenue was 6.59 million, an increase of 31.24% compared to the previous year's 5.02 million. Losses were -13.69 million, -7.42% less than in 2022.